Ichthyosis Severity News Today

Two formulations of a novel topical isotretinoin ointment formulation were associated with improvements over vehicle in patients with two types of congenital ichthyosis, according to a study.“Congenital ichthyosis (CI) is being studied because there are no FDA-approved treatments and there is a significant unmet clinical need for this lifetime challenging condition,” Joyce M. C. Teng,

Phase 3 Trial in Progress of New Ichthyosis Treatment

Yale dermatologists are playing a key role in testing a new treatment for an often-disfiguring group of skin diseases that develop in children.

Press release content from NewMediaWire. The AP news staff was not involved in its creation.

- Company announces positive clinical data of FDA-Designated Breakthrough Therapy TMB-001 demonstrating safety, efficacy and quality of life improvements...

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology - read this article along with other careers information, tips and advice on BioSpace

Rare dermatologic disease R&D is growing at a much faster rate than other fields in dermatology. Even before the data readout from our Phase 2b...

Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting - read this article along with other careers information, tips and advice on BioSpace

TMB-001 is a topical isotretinoin formulation that uses a patented IPEG technology isotretinoin delivery system.

If you are familiar with rare diseases, you know there are unique challenges associated with conducting clinical trials to evaluate potential new...